

### **Listing of Claims:**

#### **We claim:**

1. (Currently Amended) Matrix-controlled transdermal therapeutic system comprising (i) an active-ingredient impermeable cover layer, (ii) a self-adhesive matrix layer, or a plurality of matrix layers of which at least the matrix layer exposed while applying the system is self-adhesive, or one or more matrix layers whose surface remote from the cover layer and intended for adhesion at the application site is coated with an adhesive, the matrix layer(s) comprising at least one ACE inhibitor (angiotensin converting enzyme inhibitor) from the group imidapril, fosinopril, moexipril, perindopril, ramipril, spirapril, cilazapril, benazepril and/or trandolapril in the form of a dicarboxylic acid, which is derivatised to form a diester and/or a mono salt formed with acid(s), ~~in the form of a dicarboxylic acid, which is derivatised to form a derivative~~ selected from the following group  
  
diester,  
  
and  
  
mono-salt obtainable with acid(s),  
  
and (iii) a removable protective layer.
2. (Cancelled)
3. (Previously Presented) The system according to claim 1, characterised by at least one ACE inhibitor from the group imidapril, fosinopril, moexipril, perindopril, ramipril, spirapril, cilazapril and/or trandolapril in the form of a dicarboxylic acid, which is derivatised to form a diester, and/or a mono-salt formed with acid(s).

4. (Currently Amended) The system according to claim 21, wherein the ACE inhibitor is mono-sulphonic acid salt or disodium salt oftrandolaprilat or ramiprilat.
5. (Currently Amended) The system according to claim 21 characterised by an ethyl ester oftrandolapril and/or ramipril.
6. (Previously Presented) The system according to claim 1 characterised in that the ACE inhibitor carries, in addition to a first ester group, a further ester group from the following group: methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonane, decane groups and isomers thereof; the first ester group being freely selected, the first ester group being freely selected, the ACE inhibitor being a pharmaceutically acceptable compound, or the first and second ester group being identical.
7. (Previously Presented) The system according to claim 6, characterised in that the further ester group is an ethyl group.
8. (Canceled)
9. (Canceled)
10. (Currently Amended) The system according to claim 1, characterised by a mono-salt which is obtainable using an acid from the following group: inorganic acid, ~~especially hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulphuric acid and phosphoric acid~~, organic carboxylic acid, ~~especially salicylic acid, maleic acid, adipic acid, sorbic acid, malonic acid, 1,4-butanedioic acid, malic acid, pivalic acid, succinic acid, nicotinic acid, isonicotinic acid, furan-2-carboxylic acid, dichloroacetic acid and benzoic~~

acid, fatty acids, especially lauric acid, myristic acid and oleic acid, aliphatic sulphonic acid, especially methane, ethane, propane, isopropane, butane, isobutane, pentane, isopentane, hexane, heptane, octane, nonane, decane, undecane and dodecane sulphonie acid and aromatic sulphonie acid, especially toluene and benzenesulphonie acid.

11. (Previously Presented) The system according to claim 10, characterised by methanesulphonic acid as acid.

12. (Currently Amended) The system according to claim 1, characterised in that ACE inhibitors have been incorporated into the system,

(i) before formation of a mono-salt, together with acid(s) for salt formation, in equimolar ratio, separately from one another, or

(ii) as the di-salt or the mono-salt  
~~have been incorporated into the system.~~

13. (Currently Amended) The system according to claim 1, characterised by a content of ACE inhibitor(s) of from 2 to 25% by weight ~~and especially from 10 to 15% by weight~~, based on the matrix weight.

14. (Currently Amended) The system according to claim 1, characterised in that the system has, on that side of the cover layer which is remote from the matrix layer(s), ~~(iv)~~ a covering (overtape)

(i) which extends beyond the cover layer on all sides and which is provided with an adhesive that covers its surface or at least the region, in itself uninterrupted, extending beyond the cover layer, or

(ii) which covers over the surface of the cover layer but not does not extend beyond it and which is provided with an adhesive that covers its surface.

15. (Previously Presented) The system according to claim 14, characterised in that the covering (overtape) provided with an adhesive completely covers over the active-ingredient-impermeable cover layer or is provided with one or more perforations above the cover layer or is of annular shape.

16. (Previously Presented) The system according to claim 14, characterised in that the active-ingredient-impermeable cover layer and the covering provided with an adhesive are permeable to water vapour.

17. (Previously Presented) The system according to claim 14, characterised in that the active-ingredient-impermeable cover layer and the covering (overtape) provided with an adhesive are made from the same material.

18. (Previously Presented) The system according to claim 14, characterised in that the matrix layer(s) comprise(s) one or more permeation enhancers.

19. (Previously Presented) The system according to claim 18, characterised by highly disperse silicon dioxide, polyoxyethylene 7-glycerol monococoate and/or 2-octyldodecanol (Eutanol G) as permeation enhancer(s).

20. (New) The system according to claim 10, wherein (i) the inorganic acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, sulphuric acid and phosphoric

acid, (ii) the organic carboxylic acid is selected from the group consisting of salicylic acid, maleic acid, adipic acid, sorbic acid, malonic acid, 1,4-butanedioic acid, malic acid, pivalic acid, succinic acid, nicotinic acid, isonicotinic acid, furan-2-carboxylic acid, dichloroacetic acid and benzoic acid, (iii) the fatty acid is selected from the group consisting of lauric acid, myristic acid and oleic acid, (iv) the aliphatic sulphonic acid is selected from the group consisting of methane-, ethane-, propane-, isopropane-, butane-, isobutane-, pentane-, isopentane-, hexane-, heptane-, octane-, nonane-, decane-, undecane and dodecane-sulphonic acid, and (v) the aromatic sulphonic acid is selected from toluene and benzene-sulphonic acid.

21. (New) The system according to claim 13, characterized by a content of ACE inhibitor(s) of from 10 to 15% by weight based on the matrix weight.